Australia’s Monash University, along with the University of Melbourne and Taiwan’s Chang Gung University, signed a collaboration and nondisclosure agreement centering on the development of new drugs for potential use against viruses, including SARS-CoV-2—the virus behind the COVID-19 pandemic. Under this cooperative research agreement, Chang Gung University will provide strains of SARS-CoV-2 and other viruses while Monash University will focus on the study of ivermectin as a possible treatment for SARS-CoV-2. All of the research will be carried out in Taiwanese laboratories and led by a prominent research virologist and director of the Chang Gung University Research Center for Emerging Viral Infections.
Australian Research into Ivermectin Stimulates Taiwanese Interest
This research collaboration was prompted by a Taiwanese ministry after reviewing the laboratory studies from Monash University’s Biomedicine Discovery Institute and the University of Melbourne’s Peter Doherty Institute for Infection and Immunity, showcasing that ivermectin can eliminate SARS-CoV-2 in cells within two days in a laboratory setting.
Consequently, the Taipei Economic and Cultural Office in Austr...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).